HOME >> MEDICINE >> NEWS
New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer

paradigm for cancer treatment, and is a promising area of research. This study must be viewed cautiously, however, as we are comparing statistics from historical control groups.

Pertuzumab is a single-agent antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to pair with other HER family members (HER1, HER2, HER3 and HER4). If the pairing process (called dimerization) is not interrupted, the binding of these growth factors activates an intracellular signaling pathway that leads to tumor proliferation.

While other drugs such as docetaxel have shown to benefit men with advanced prostate cancer, no other second-line therapy (a treatment given when an initial treatment (first-line therapy) does not work or stops working) to date has shown to prolong survival.

Previous research published by cancer researchers at Cedars-Sinai and other institutions has shown that pertuzumab affects the growth of several other types of cancers, including breast, ovarian and lung cancer, and that the drug may also prolong survival for patients with advanced ovarian cancer.

In the current study, the pertuzumab was well-tolerated but no objective tumor shrinkages were observed. No decline in PSA (prostate-specific antigen; a tumor marker) levels was detected in patients during the study. According to the researchers, this study raises a question long debated in prostate cancer literature: what should clinical outcome standards or end point be the for studies involving patients with advanced, intractable prostate cancer who have limited treatment options.

The next step for researchers is to test the pertuzumab on a larger group of patients in a randomized fashion, and to analyze data that is not retrospective.

Prostate cancer is the most common type of cancer found in American men, other than skin cancer and is the second leading cause of cancer death in men. The American Cancer Society estim
'"/>

Contact: Simi Singer
simi.singer@cshs.org
310-423-4768
Cedars-Sinai Medical Center
16-Feb-2007


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. Early-morning Friday classes may prevent students from getting sloppy on thirsty Thursdays
3. Panel offers guidelines on skin reactions to new class of cancer drugs
4. UK researchers find new class of nontoxic cancer treatments
5. New class of HIV drug attacks previously untargeted enzyme
6. Sleep disturbances affect classroom performance
7. Simple classification can help define and predict limb-threatening diabetic infections
8. World-class Biomedical Research Center to be in West London
9. A new way of classifying addictive drugs
10. Phys ed class more effective when theres more talking
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
(Date:7/7/2015)... ... July 07, 2015 , ... ... strong managerial expertise to oversee large healthcare operations and their success is ... partners, insurance companies, and regulators. American Sentinel University, an innovative, accredited provider ...
(Date:7/7/2015)... ... July 07, 2015 , ... On May 29, 2015, Health Canada ... the use of gluten-free claims for gluten free oats and foods that contain them ... Gluten-Free Certification Program (GFCP) to include gluten-free oat products in Canada,” says Frank ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... today announced they have been selected by the Department of Vermont Health Access ... its Medicaid Management Information System (MMIS) and Integrated Contact Center System project. , ...
(Date:7/6/2015)... ... July 06, 2015 , ... Human induced pluripotent ... iPSCs are generated from adult cells, such as blood or skin, can replicate ... human body. , iPSC-derived cardiomyocytes have proven valuable in helping ...
(Date:7/6/2015)... ... July 06, 2015 , ... University of Pittsburgh Cancer Institute ... thyroid cancer testing to reflect newly available tests that better incorporate personalized medicine into ... to interpret thyroid cancer tests is published in the July issue of the scientific ...
Breaking Medicine News(10 mins):Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 3Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 4Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5
(Date:7/6/2015)... 6, 2015  Impax Laboratories, Inc. (NASDAQ: IPXL ... second quarter 2015 financial results on Monday, August 10, ... markets. The Company will host a conference call and ... Eastern Time on August 10, 2015. The ... the Investor Relations section of the Company,s Web site ...
(Date:7/6/2015)... HORSHAM, Pa. , July 6, 2015 /PRNewswire/ ... procedure-based, bone fixation concept the FlowerCube™, announced today ... approval opens the opportunity for significant expansion of ...   The approval encompasses Flower Orthopedics, ... fixation solutions for upper and lower extremities. Consisting ...
(Date:7/6/2015)... NEWTOWN, Pa. , July 6, 2015 /PRNewswire/ ... services and technology provider, today announced that it ... retention firm, MediciGroup ® , Inc. (Medici).  The ... Access to Patients, LLC.  Medici also provides a ... finds missing patients globally.  Together with Medici, ...
Breaking Medicine Technology:Impax to Report Second Quarter 2015 Results on August 10, 2015 2Flower Orthopedics cleared to enter the European Union 2BioClinica Acquires MediciGroup 2BioClinica Acquires MediciGroup 3
Cached News: